Announcement PDF RNS Number : 6200C N4 Pharma PLC 24 February 2022 24 February 2022 N4 Pharma Plc ("N4 Pharma" or the "Company") Notice of Annual General Meeting and Posting of Annual Report and Accounts N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that the Company's audited accounts for the year ended 31 December 2021, together with the notice of Annual General Meeting ("AGM"), are now available on the Company's website www.n4pharma.com and will be posted to shareholders today. The AGM will be held at 11.00am on 24 March 2022 at Shakespeare Martineau LLP, 6th Floor 60 Gracechurch Street, London, EC3V 0HR. Enquiries: N4 Pharma Plc Nigel Theobald, CEO Luke Cairns, Executive Director Via IFC Advisory SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking) Tel: +44 (0)20 3470 0470 Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker Tel: +44 (0)20 3657 0050 IFC Advisory Limited Financial PR Graham Herring Zach Cohen Tel: +44 (0)20 3934 6630 About N4 Pharma N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®. N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END MSCSEUFMDEESEIE